$VRP #Verona Pharma Verona Pharma plc: PDMR Dealings
Verona Pharma plc: PDMR Dealings LONDON, United Kingdom and RALEIGH, N.C., July 17, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a...
View Article$VRP #Verona Pharma Closing of Financing, Issued Share Capital and Total...
Closing of Financing, Issued Share Capital and Total Voting Rights NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD...
View Article$VRP #Verona Pharma Verona Pharma plc: TR-1: Standard form for notification...
Verona Pharma plc: TR-1: Standard form for notification of major holdings LONDON and RALEIGH, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer...
View Article$VRP #Verona Pharma Verona Pharma to Announce Interim Results for the Three...
Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc...
View Article$VRP #Verona Pharma Verona Pharma plc: TR-1: Standard form for notification...
Verona Pharma plc: TR-1: Standard form for notification of major holdings LONDON and RALEIGH, N.C., July 30, 2020 (GLOBE NEWSWIRE) -- NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer...
View Article$VRP #Verona Pharma Verona Pharma Announces August 2020 Virtual Investor...
Verona Pharma Announces August 2020 Virtual Investor Conference Participation LONDON and RALEIGH, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”),...
View Article$VRP #Verona Pharma Verona Pharma plc: Issue of Equity, PDMR Dealings Total...
Verona Pharma plc: Issue of Equity, PDMR Dealings & Total Voting Rights LONDON and RALEIGH, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or...
View Article$VRP #Verona Pharma Verona Pharma plc: TR-1: Standard form for notification...
Verona Pharma plc: TR-1: Standard form for notification of major holdings LONDON and RALEIGH, N.C., Aug. 07, 2020 (GLOBE NEWSWIRE) -- NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer...
View Article$VRP #Verona Pharma Verona Pharma plc Operational Update and Financial...
Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020 Completed $200 million private placement post period Phase 3 COPD clinical trials planned to...
View Article$VRP #Verona Pharma Verona Pharma Initiates Multiple Dose Part of Phase 2...
Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD Results expected in the first half of 2021 LONDON and RALEIGH, N.C., Aug. 19, 2020...
View Article$VRP #Verona Pharma Verona Pharma to Present Phase 2b data with Ensifentrine...
Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020 New subgroup analysis supports ensifentrine’s efficacy in symptomatic...
View Article$VRP #Verona Pharma Verona Pharma plc: Grant of RADSUs and PDMR Dealings
Verona Pharma plc: Grant of RADSUs and PDMR Dealings LONDON and RALEIGH, N.C., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a...
View Article$VRP #Verona Pharma Verona Pharma to Present at H.C. Wainwright 22nd Annual...
Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference LONDON and RALEIGH, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA)...
View Article$VRP #Verona Pharma Verona Pharma Initiates Pilot Study with pMDI...
Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 LONDON and RALEIGH, N.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)...
View Article$VRP #Verona Pharma Verona Pharma to Present Phase 2b COPD Symptom and...
| Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020 [...]
View Article$VRP #Verona Pharma Verona Pharma to Announce Interim Results for the Three...
Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update LONDON and RALEIGH, N.C., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Verona Pharma...
View Article$VRP #Verona Pharma Verona Pharma plc : Update on AIM Delisting
Verona Pharma plc : Update on AIM Delisting LONDON and RALEIGH, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), provides a...
View Article$VRP #Verona Pharma Verona Pharma plc Operational Update and Financial...
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020 Initiated ENHANCE Phase 3 clinical trials in COPD Completed $200 million private...
View Article$VRP #Verona Pharma Verona Pharma Announces November 2020 Virtual Investor...
Verona Pharma Announces November 2020 Virtual Investor Conference Participation LONDON and RALEIGH, N.C., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a...
View Article$VRP #Verona Pharma Verona Pharma Secures up to $30 Million Debt Financing...
Verona Pharma Secures up to $30 Million Debt Financing from Silicon Valley Bank Non-dilutive capital to provide further financial flexibility LONDON and RALEIGH, N.C., Nov. 23, 2020 (GLOBE NEWSWIRE)...
View Article$VRP #Verona Pharma Verona Pharma to Present at H.C. Wainwright Virtual...
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference LONDON and RALEIGH, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a...
View Article$VRP #Verona Pharma Verona Pharma Completes Enrollment in Pilot Study of pMDI...
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 Top-line results expected in 2Q 2021 LONDON and RALEIGH, N.C., Jan. 14, 2021 (GLOBE...
View Article$VRP #Verona Pharma CORRECTING and REPLACING -- Verona Pharma Reports...
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD LONDON and RALEIGH, N.C., Feb. 02, 2021 (GLOBE NEWSWIRE) -- In a release issued...
View Article$VRP #Verona Pharma Verona Pharma to Report Fourth Quarter and Full Year 2020...
Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA)...
View Article$VRP #Verona Pharma ... Monthly LMI Update Independent Investment Research
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR...
View Article
